Terms: = Prostate cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
480 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
3. Clinical safety and efficacy of microwave ablation for small renal masses.
Foret A; Haaga CB; Jain S; Baumgartner CO; Escott M; Henderson BR; O'Brien ST; Delacroix SE; Gills JRR; Westerman ME
Int Braz J Urol; 2024; 50(3):277-286. PubMed ID: 38598830
[TBL] [Abstract] [Full Text] [Related]
4. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic prostate cancer.
Uzelac M; Xin R; Ongkeko WM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
[TBL] [Abstract] [Full Text] [Related]
5. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
[TBL] [Abstract] [Full Text] [Related]
6. Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression.
Xiong Z; Tong T; Xie Z; Yu S; Zhuang R; Jia Q; Peng S; Li B; Xie J; Li K; Wu J; Huang H
Biomater Sci; 2024 Jan; 12(3):650-659. PubMed ID: 38168678
[TBL] [Abstract] [Full Text] [Related]
7. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of egfr
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract] [Full Text] [Related]
8. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant prostate cancer in a National Health Care Delivery System.
Nguyen CB; Kobe C; Kumbier KE; Bauman J; Burns JA; Tsao PA; Sparks JB; Skolarus TA; Caram MEV
JCO Oncol Pract; 2024 Jan; 20(1):59-68. PubMed ID: 38085028
[TBL] [Abstract] [Full Text] [Related]
9. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/egfr.
Kim S; Park JM; Park S; Jung E; Ko D; Park M; Seo J; Nam KD; Kang YK; Lee K; Farrand L; Kim YJ; Kim JY; Seo JH
J Exp Clin Cancer Res; 2023 Nov; 42(1):292. PubMed ID: 37924112
[TBL] [Abstract] [Full Text] [Related]
10. egfr-mediated hyperacetylation of tubulin induced docetaxel resistance by downregulation of HDAC6 and upregulation of MCAK and PLK1 in prostate cancer cells.
Pu YS; Huang CY; Wu HL; Wu JH; Su YF; Yu CR; Lu CY; Wu WJ; Huang SP; Huang YT; Hour TC
Kaohsiung J Med Sci; 2024 Jan; 40(1):23-34. PubMed ID: 37916740
[TBL] [Abstract] [Full Text] [Related]
11. The Network Pharmacology Analysis of Tonifying Yang Formula for the treatment of Diminished Ovarian Reserve.
Ma Q; Wu X; Chen D; Li W; Wu J; Shen M; Ye C; Tan Y; Guo Q
Altern Ther Health Med; 2024 Mar; 30(3):176-184. PubMed ID: 37883761
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Nephrotoxicity of
Steinhelfer L; Lunger L; Cala L; Pfob CH; Lapa C; Hartrampf PE; Buck AK; Schäfer H; Schmaderer C; Tauber R; Brosch-Lenz J; Haller B; Meissner VH; Knorr K; Weber WA; Eiber M
J Nucl Med; 2024 Jan; 65(1):79-84. PubMed ID: 37857504
[TBL] [Abstract] [Full Text] [Related]
13. RGD-decorated nanoliposomes for combined delivery of arsenic trioxide and curcumin to prostate cancer cells.
Khosravani F; Amiri F; Mahmoudi R; Morshedi D; Kobarfard F; Alipour M; Hosseini E; Bardania H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2347-2357. PubMed ID: 37831114
[TBL] [Abstract] [Full Text] [Related]
14. miR-199a/214 cluster enhances prostate cancer sensitiveness to nimotuzumab via targeting TBL1XR1.
Hu S; Zhou Q; Lu Q; Guo X; Wang Y; Duan YX
Kaohsiung J Med Sci; 2023 Dec; 39(12):1178-1189. PubMed ID: 37772770
[TBL] [Abstract] [Full Text] [Related]
15. Rhizochalinin Exhibits Anticancer Activity and Synergizes with egfr Inhibitors in Glioblastoma In Vitro Models.
Dyshlovoy SA; Hauschild J; Venz S; Krisp C; Kolbe K; Zapf S; Heinemann S; Fita KD; Shubina LK; Makarieva TN; Guzii AG; Rohlfing T; Kaune M; Busenbender T; Mair T; Moritz M; Poverennaya EV; Schlüter H; Serdyuk V; Stonik VA; Dierlamm J; Bokemeyer C; Mohme M; Westphal M; Lamszus K; von Amsberg G; Maire CL
Mol Pharm; 2023 Oct; 20(10):4994-5005. PubMed ID: 37733943
[TBL] [Abstract] [Full Text] [Related]
16. Cardiorespiratory fitness and BMI measured in youth and 5-year mortality after site-specific cancer diagnoses in men-A population-based cohort study with register linkage.
Onerup A; Mehlig K; Ekblom-Bak E; Lissner L; Börjesson M; Åberg M
Cancer Med; 2023 Oct; 12(19):20000-20014. PubMed ID: 37732468
[TBL] [Abstract] [Full Text] [Related]
17. Targeted Therapy for cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.
Choi HY; Chang JE
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686423
[TBL] [Abstract] [Full Text] [Related]
18. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract] [Full Text] [Related]
19. Combination of Lycopene and Curcumin Synergistically Alleviates Testosterone-Propionate-Induced Benign Prostatic Hyperplasia in Sprague Dawley Rats via Modulating Inflammation and Proliferation.
Wang S; He W; Li W; Zhou JR; Du Z
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446563
[TBL] [Abstract] [Full Text] [Related]
20. Dependency of Tamoxifen Sensitive and Resistant ER
Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
[TBL] [Abstract] [Full Text] [Related]
[Next]
